36,085 Shares in Galectin Therapeutics Inc. (NASDAQ:GALT) Bought by Solutions 4 Wealth Ltd

Solutions 4 Wealth Ltd bought a new stake in Galectin Therapeutics Inc. (NASDAQ:GALT) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 36,085 shares of the company’s stock, valued at approximately $60,000. Solutions 4 Wealth Ltd owned 0.06% of Galectin Therapeutics at the end of the most recent quarter.

Several other large investors also recently modified their holdings of GALT. D.A. Davidson & CO. raised its stake in shares of Galectin Therapeutics by 15.2% in the 3rd quarter. D.A. Davidson & CO. now owns 37,825 shares of the company’s stock valued at $73,000 after purchasing an additional 5,000 shares during the period. Retirement Guys Formula LLC raised its holdings in shares of Galectin Therapeutics by 87.0% in the fourth quarter. Retirement Guys Formula LLC now owns 21,500 shares of the company’s stock valued at $36,000 after purchasing an additional 10,000 shares during the last quarter. Beacon Capital Management LLC grew its position in Galectin Therapeutics by 89.6% in the fourth quarter. Beacon Capital Management LLC now owns 23,905 shares of the company’s stock valued at $40,000 after purchasing an additional 11,300 shares in the last quarter. Finally, AE Wealth Management LLC lifted its position in Galectin Therapeutics by 72.7% during the 3rd quarter. AE Wealth Management LLC now owns 26,841 shares of the company’s stock worth $52,000 after buying an additional 11,300 shares in the last quarter. 11.68% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on GALT. HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Galectin Therapeutics in a report on Tuesday, April 9th. StockNews.com raised shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, April 1st.

Galectin Therapeutics Price Performance

NASDAQ GALT traded down $0.13 on Thursday, reaching $3.37. The stock had a trading volume of 250,289 shares, compared to its average volume of 134,129. The company has a market cap of $208.60 million, a P/E ratio of -4.45 and a beta of 0.72. The firm has a fifty day moving average of $2.71 and a two-hundred day moving average of $2.15. Galectin Therapeutics Inc. has a 1-year low of $1.28 and a 1-year high of $4.27.

Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings results on Friday, March 29th. The company reported ($0.16) EPS for the quarter. Research analysts predict that Galectin Therapeutics Inc. will post -0.66 EPS for the current fiscal year.

Insiders Place Their Bets

In other Galectin Therapeutics news, major shareholder James C. Czirr sold 21,323 shares of the stock in a transaction dated Monday, April 22nd. The shares were sold at an average price of $3.06, for a total transaction of $65,248.38. Following the sale, the insider now directly owns 5,925,884 shares in the company, valued at $18,133,205.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have purchased a total of 4,500 shares of company stock worth $14,360 in the last 90 days. Company insiders own 52.70% of the company’s stock.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.